Adagene (ADAG) stock

Market cap $169MShares as of Dec 31

$2.85

-2.73%

Market closed. Prices as of Friday's close.

Not scored

Breakaway doesn't score ADAG. It is too thinly traded for a fair Quality Score.

Healthcare · Biotech

Next2026“…with and without liver metastases, sponsored and conducted by Incyte, is expected to begin later this year…”Trial start · 6-K, Aug 12

Follow ADAG's trial news. Pro members can get an alert when Adagene files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when ADAG files news on its trialsSee it live, free for 24 hours. No account needed. Then keep going with a free account.

We do the work for you. 3,243 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live. So can you, free, with no account.

What's next for ADAG, and how long its cash lasts

From Adagene’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

2026“A Phase 1 combination study in 3L MSS CRC patients with and without liver metastases, sponsored and conducted by Incyte, is expected to begin later this year.”Trial start · 6-K, Aug 12

What it means: when a trial begins, or reaches the stage the company named.

A trial underway: ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid TumorsPhase 1/2 · Recruiting · 186 people · main data estimated Oct 31, 2026 · NCT05405595

1 more trial, 1 more milestone and 28 filings, for Pro members.

Cash runway Dec 31, 2025 balance sheet

$74.5M in cash

Fewer than four quarters of cash flow are on file.

What it means: a runway is counted only when each of the last four quarters used cash. The company's own estimate is “into late 2028” (8-K, Aug 12). It has raised money since that balance sheet, which is not counted here.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (F-3, filed May 9, 2025)
At-the-market share sales program (424B5, filed May 30, 2025)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

CFO Man Kin Tam bought 2,000 shares on Sep 23. 3 more insider trades this year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

Get an optional alert when Peter Luo buys or sells

For Pro members: every trade, and Peter Luo’s 9 filings and quotes.

Get an optional alert when ADAG files news on its trialsSee it live, free for 24 hours. No account needed. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

In 27 daysFDA decisionIn 27 days · FDA decisionINOInovio PharmaceuticalsINO-3107INOInovio Pharmaceuticals · $125MINO-3107Under FDA review
In 38 daysANDA decisionIn 38 days · ANDA decisionNRXPNRX PharmaceuticalsDrug not namedNRXPNRX Pharmaceuticals · $123MDrug not namedA generic, under FDA review
In 50 daysFDA decisionIn 50 days · FDA decisionCAPRCapricor TherapeuticsDrug not namedCAPRCapricor Therapeutics · $520MDrug not namedUnder FDA review

8 more FDA dates and 114 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

ADAG's latest filings

An insider's trade or awardForm 4, filed Oct 2
A report to the SEC6-K, filed Sep 25
Prospectus for a sale of securities424B5, filed Apr 2

23 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why ADAG isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares a day. ADAG trades about 216,000 shares a day. A stock that clears every mark is scored from the next weekly rebuild.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price on this page is delayed at least 15 minutes. The share count and the filings are shown as filed.